
|Videos|June 5, 2023
Pathophysiology of AD Treatments
Author(s)Andrew Blauvelt, MD
Andrew Blauvelt, MD, provides an overview of the significance of JAK/Stat pathway inhibition in targeting the pathophysiology of atopic dermatology (AD).
Advertisement
Episodes in this series

Advertisement
Latest CME
Advertisement
Advertisement
Trending on HCPLive
1
Brensocatib Patient Selection Evolves 1 Year After FDA Approval
2
CKM Syndrome, Artery Damage Prevalence Higher in Young Adults than Previously Believed
3
ABTECT Maintenance Data Show Durable Remission in UC, With Remo Panaccione, MD
4
Why Mentorship Matters Most for Dermatology Trainees
5


















































































